Psoriasis Trial, Recruiting (NCT05928169)

Psoriasis Trial, Recruiting NCT05928169 Sponsor: University Hospital Schleswig-Holstein Condition: Psoriasis

Printed from Voxsanity (voxsanity.com.au) — NCT05928169 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Psoriasis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed by a dermatologist (skin doctor) with an inflammatory skin disease.
You are willing and able to give your written consent to take part in the study.

Who may not be able to join:

You (or your legal guardian, if applicable) are unable to provide written consent to participate.
You are currently pregnant or breastfeeding.
You are already taking part in another clinical trial at the same time.
You have used certain medicines that affect the immune system (taken by mouth or injection), light therapy, or certain newer injectable treatments (such as dupilumab or tralokinumab) recently — specifically within the last 4 weeks for some treatments, or within the last 3 months for others (confirm with trial site).
You have applied certain creams or ointments — such as steroid creams, calcineurin inhibitor creams, or moisturisers — to the skin area being studied within the 24 hours before your sample is collected.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sascha Gerdes, MD, University Hospital Schleswig-Holstein

Phone: 0049431500

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05928169

Sponsor: University Hospital Schleswig-Holstein

Phase: Not Applicable

Status: Recruiting

Condition: Psoriasis

Trial contact: 0049431500

More information: https://clinicaltrials.gov/study/NCT05928169

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed by a dermatologist (skin doctor) with an inflammatory skin disease.
You are willing and able to give your written consent to take part in the study.

Who may not be able to join:

You (or your legal guardian, if applicable) are unable to provide written consent to participate.
You are currently pregnant or breastfeeding.
You are already taking part in another clinical trial at the same time.
You have used certain medicines that affect the immune system (taken by mouth or injection), light therapy, or certain newer injectable treatments (such as dupilumab or tralokinumab) recently — specifically within the last 4 weeks for some treatments, or within the last 3 months for others (confirm with trial site).
You have applied certain creams or ointments — such as steroid creams, calcineurin inhibitor creams, or moisturisers — to the skin area being studied within the 24 hours before your sample is collected.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University Hospital Schleswig-Holstein

Registry

ClinicalTrials.gov

Start date

1 May 2023

Est. completion

30 April 2032

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Physician-assessed global disease activity; Patient-reported global disease activity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov